Preoperative serum level of inhibin a is an independent prognostic factor for the survival of postmenopausal women with epithelial ovarian carcinoma

Cancer

Volumn 85, Issue 2, 1999, Pages 465-471

  Frias Jr , Antonio E ^a   Li, Honghze ^b   Keeney, Gary L ^b   Podratz, Karl C ^b   Woodruff, Teresa K ^c  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Follicle stimulating hormone; Granulosa; Ovary; Testis; Transforming growth factor

Indexed keywords

ACTIVIN A; FOLLITROPIN; INHIBIN A; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE CLASSIFICATION; FEMALE; HUMAN; OVARY CARCINOMA; POSTMENOPAUSE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS;

AGED; AGED, 80 AND OVER; CARCINOMA; COHORT STUDIES; FEMALE; HUMANS; INHIBINS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PEPTIDES; POSTMENOPAUSE; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0344527870     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990115)85:2<465::AID-CNCR26>3.0.CO;2-W     Document Type: Article

References (33)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics. CA Cancer J Clin 1998;48:6-29.
2. Woodruff TK and Mather J. Inhibin, Activin and the Female Reproductive Axis. Annu Rev Physiol 1995;57:219-44.
3. Woodruff TK, Lyon RJ, Hansen SE, Rice GC, Mather JP. Inhibin and activin locally regulate rat ovarian folliculogenesis. Endocrinology 1990;127:3196-205.
4. Alak BM, Smith GD, Woodruff TK, Stouffer RL, Wolf DP. Enhancement of Primate Oocyte Maturation and Fertilization In Vitro by Inhibin A and Actin A. Ferttil Steril 1996;66: 646-53.
5. Woodruff TK. Regulation of Cellular and System Function by Actin. Biochem Pharmacol 1998;55:953-63.
6. Blaakaer J, Micic S, Morris ID, Hording U, Bennett P, Toftager-Larsen K, et al. Immunoreactive inhibin production in postmenopausal women with malignant epithelial ovarian tumors. Eur J Obstet Gynecol Reprod Biol 1993;52:105-10.
7. Healy D, Burger HG, Mamers P, Jobling TJ, Mohan B, Quinn M, et al. Elevated serum inhibin concentrations in post-menopausal women with ovarian tumors. N Engl J Med 1993;21:1539-42.
8. Burger HG, Fuller PJ. The inhibin/activin family and ovarian cancer. Trends Endocrinol Metab 1996;7:197-202.
9. Lappohn RE, Burger HG, Bouma J, Banagh M, Krans M, deBruijn WA. Inhibin as a marker for granulosa cell tumors. N Engl J Med 1989;321:790-3.
10. Matzuk MM, Finegold MJ, Su JJ, Hsueh AJW, Bradley A. Alpha inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 1992;360:313-9.
11. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu L, Bradley A. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin deficient mice. Proc Natl Acad Sci USA 1994;91:8817-21.
12. Hamilton TC. Ovarian cancer. Part I: Biology. Curr Probl Cancer 1992;16:1-57.
13. Wimalasena J, Dostal R, Meehan D. Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth. Gynecol Oncol 1992;46:345-50.
14. Fuller PJ, Verity K, Shen Y, Mamers P, Jobling T, Burger HG. No evidence of a role for mutations or polymorphisms of the follicle-stimulating hormone receptor in ovarian granulosa cell tumors. J Clin Endocrinol Metab 1998;83:274-9.
15. Di Simone N, Crowley WF, Wang Q, Sluss PM, Schneyer Al. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 1996;137:486-94.
16. Groome NP, Illingworth PJ, O'Brien M, Cooke I, Ganesan TS, Baird DT, et al. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin Endocrinol (Oxf) 1994;40:717-23.
17. Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996;81:1401-5.
18. Groome NP, Illingworth PJ, O'Brien M, Priddle J, Weaver K, McNeilly AS. Quantification of inhibin pro-alpha C-containing forms in human serum by a new ultrasensitive two-site enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 1995;80:2926-32.
19. Wong W, Garg S, Woodruff T, Bald L, Fendly B, Lofgren JA. Monoclonal antibody based ELISAs for measurement of activins in biological fluids. J Immunol Methods 1993;165:1-10.
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
21. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc 1972;34:187-220.
22. Kumar TR, Wang Y, Matzuk MM. Gonadotropins are essential modifier factors for gonadal tumor development in inhibin-deficient mice. Endocrinology 1996;137:4210-6.
23. Coerver KA, Woodruff TK, Finegold MI, Mather J, Bradley A, Matzuk MM. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. Mol Endocrinol 1996;10:534-43.
24. Attisano L, Wrana JL, Cheifetz S, Massague J. Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. Cell 1992;68:97-108.
25. Alexander JM, Bikkal HA, Zervas NT, Laws ER Jr., Klibanski A. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas. J Clin Endocrinol Metab 1996;81:783-90.
26. Watson RH, Roy WJ Jr., Davis M, Hitchcock A, Campbell IG. Loss of heterozygosity at the alpha-inhibin locus on chromosome 2q is not a feature of human granulosa cell tumors. Gynecol Oncol 1997;65:387-90.
27. de Winter JP, Timmerman MA, Vanderstichele HM, Klaij IA, Grootenhuis AJ, Rommerts FF, et al. Testicular Leydig cells in vitro secrete only inhibin alpha-subunits, whereas Leydig cell tumors can secrete bioactive inhibin. Mol Cell Endocrinol 1992;83:105-15.
28. Draper LB, Matzuk MM, Roberts VJ, Cox E, Weiss J, Mather JP, et al. Identification of an inhibin receptor in gonadal tumors from inhibin alpha-subunit knockout mice. J Biol Chem 1998;273:398-403.
29. Flemming P, Grothe W, Maschek H, Petry KU, Wellman A, Georgii A. The site of inhibin production in ovarian neoplasms. Histopathology 1996;29:465-8.
30. Gurusinghe CJ, Healy DL, Jobling T, Mamers P, Burger HG. Inhibin and activin are demonstrable by immunohistochemistry in ovarian tumor tissue. Gynecol Oncol 1995;57: 27-32.
31. Arora DS, Cooke IE, Ganesan TS, Ramsdale J, Manek S, Charnock FML et al. Immunohistochemical expression of inhibin/activin subunits in epithelial and granulosa cell tumors of the ovary. J Pathol 1997;181:413-8.
32. Zheng W, Luo MP, Welt C, Lambert-Messerlian G, Sung CJ, Zhang Z, et al. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol 1998;69:23-31.
33. Cooke I, O'Brien MO, Charnock FM, Groome N, Ganesan TS. Inhibin as a marker for ovarian cancer. Br J Cancer 1995;71:1046-50.